‹ All stocks

NeuroSense Therapeutics Ltd.

NRSN · NASDAQ · Healthcare

$4.13

▲ $4.13 (1.72%)

1D 7D 1M 3M 1Y All

Day range

$3.96 – $4.54

Year range

$0.33 – $26.60

Open

$4.06

Previous close

—

Market cap

$7.30M

Volume (24h)

$3.0K

Volume (52w)

$12.44K

Performance

▼ -19.02%

▼ -50.61%

▼ -70.84%

▼ -71.36%

▼ -82.35%

YTD

▼ -73.52%

▼ -65.90%

▼ -94.89%

All-time

▼ -94.89%

Key statistics

P/E ratio

-0.47

EPS (TTM)

$-8.80

Dividend yield

—

Dividend (TTM)

—

Payout ratio

—

Shares outstanding

1.8M

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.

Visit website

Country: United States of America

LLY Eli Lilly and Company	$1143.12	-0.59%
JNJ Johnson & Johnson	$252.93	-2.22%
ABBV AbbVie	$265.76	2.20%
MRK Merck & Co.	$139.54	-2.97%
UNH UnitedHealth Group Incorp…	$378.58	3.66%